Vertex Pharmaceuticals Inc - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance

More Details of Vertex Pharmaceuticals Inc Company

Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on investing in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has four approved medicines that treat the underlying cause of cystic fibrosis (CF), and one approved therapy that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT). Its pipeline includes clinical-stage programs in CF, SCD, TDT, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, myotonic dystrophy type 1 and alpha-1 antitrypsin deficiency. Its marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). It is developing non-autologous (allogeneic) fully differentiated, stem-cell derived islet cell therapies designed to replace insulin-producing islet cells that are destroyed in people with T1D.

Vertex Pharmaceuticals Inc Info



Ticker SymbolVRTX

Company nameVertex Pharmaceuticals Inc

IPO dateJul 24, 1991

CEODr. Reshma Kewalramani

Number of employees6100

Security typeOrdinary Share

Fiscal year-endJul 24

Address50 Northern Avenue

CityBOSTON

Stock exchangeNASDAQ Global Select Consolidated

CountryUnited States of America

Postal code02210

Phone16173416393

Websitehttps://www.vrtx.com/

Ticker SymbolVRTX

IPO dateJul 24, 1991

CEODr. Reshma Kewalramani

Company Executives of Vertex Pharmaceuticals Inc



Name

Name/Position

Position

Shareholding

Change

Dr. Reshma Kewalramani

President, Chief Executive Officer, Director

51.81K

+23.92%

Mr. Bruce I. Sachs

Lead Independent Director

45.00K

+12.50%

Dr. Carmen Bozic, M.D.

Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer

32.67K

+40.46%

Dr. Ourania (Nia) Tatsis, Ph.D.

Executive Vice President, Chief Regulatory and Quality Officer

30.30K

+19.95%

Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.

Executive Chairman of the Board

24.47K

--

Mr. Duncan Mckechnie

Executive Vice President, Chief Commercial Officer

16.13K

--

Mr. Jonathan Biller, J.D.

Executive Vice President, Chief Legal Officer

15.65K

-11.09%

Mr. Lloyd A. Carney

Independent Director

7.12K

+12.60%

Dr. Sangeeta N. Bhatia, M.D., Ph.D.

Independent Director

4.57K

-5.51%

Ms. Jennifer J. Schneider

Independent Director

1.72K

+86.33%

Name

Name/Position

Position

Shareholding

Change

Dr. Reshma Kewalramani

President, Chief Executive Officer, Director

51.81K

+23.92%

Mr. Bruce I. Sachs

Lead Independent Director

45.00K

+12.50%

Dr. Carmen Bozic, M.D.

Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer

32.67K

+40.46%

Dr. Ourania (Nia) Tatsis, Ph.D.

Executive Vice President, Chief Regulatory and Quality Officer

30.30K

+19.95%

Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.

Executive Chairman of the Board

24.47K

--

Mr. Duncan Mckechnie

Executive Vice President, Chief Commercial Officer

16.13K

--

Revenue Breakdown

Currency: USDUpdated: Mon, Oct 6

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

By BusinessUSD

Name

Revenue

Proportion

TRIKAFTA

2.55B

86.65%

Other product revenues

205.70M

6.99%

ALYFTREK

156.80M

5.33%

CASGEVY

30.40M

1.03%

By RegionUSD

Name

Revenue

Proportion

United States

1.83B

62.08%

Europe

910.90M

30.94%

Other

205.60M

6.98%

By Business

By Region

By BusinessUSD

Name

Revenue

Proportion

TRIKAFTA

2.55B

86.65%

Other product revenues

205.70M

6.99%

ALYFTREK

156.80M

5.33%

CASGEVY

30.40M

1.03%

Shareholding Stats

Updated: Sun, Aug 17

Shareholders

Shareholder Types

Shareholders

Proportion

Capital World Investors

11.21%

The Vanguard Group, Inc.

9.31%

Capital Research Global Investors

6.28%

BlackRock Institutional Trust Company, N.A.

5.52%

State Street Investment Management (US)

4.59%

Other

63.09%

Shareholders

Proportion

Capital World Investors

11.21%

The Vanguard Group, Inc.

9.31%

Capital Research Global Investors

6.28%

BlackRock Institutional Trust Company, N.A.

5.52%

State Street Investment Management (US)

4.59%

Other

63.09%

Shareholder Types

Shareholders

Proportion

Investment Advisor

60.58%

Investment Advisor/Hedge Fund

27.28%

Research Firm

2.54%

Pension Fund

2.27%

Bank and Trust

2.01%

Sovereign Wealth Fund

1.49%

Hedge Fund

0.70%

Individual Investor

0.14%

Insurance Company

0.12%

Other

2.88%

Institutional Shareholding



Updated: Wed, Oct 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q3

2924

248.95M

97.09%

-3.97M

2025Q2

2933

252.71M

98.56%

+2.47M

2025Q1

2977

252.24M

98.22%

-39.54K

2024Q4

2877

248.76M

96.87%

-2.25M

2024Q3

2786

247.87M

96.18%

-4.19M

2024Q2

2747

248.36M

96.27%

-4.14M

2024Q1

2680

247.63M

95.87%

-4.48M

2023Q4

2608

247.92M

96.20%

-4.51M

2023Q3

2477

248.64M

96.45%

-6.19M

2023Q2

2488

248.89M

96.55%

-7.11M

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

Capital World Investors

28.73M

11.21%

+198.84K

+0.70%

Jun 30, 2025

The Vanguard Group, Inc.

23.86M

9.31%

+479.23K

+2.05%

Jun 30, 2025

Capital Research Global Investors

16.11M

6.28%

+1.57M

+10.81%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

14.15M

5.52%

+156.31K

+1.12%

Jun 30, 2025

State Street Investment Management (US)

11.78M

4.59%

-13.43K

-0.11%

Jun 30, 2025

Fidelity Management & Research Company LLC

6.30M

2.46%

-1.32M

-17.28%

Jun 30, 2025

Geode Capital Management, L.L.C.

5.93M

2.31%

+166.99K

+2.90%

Jun 30, 2025

Invesco Capital Management (QQQ Trust)

5.26M

2.05%

-18.59K

-0.35%

Aug 31, 2025

Wellington Management Company, LLP

4.81M

1.88%

-641.36K

-11.76%

Jun 30, 2025

AllianceBernstein L.P.

4.38M

1.71%

+424.81K

+10.75%

Jun 30, 2025

Related ETFs



Updated: Sat, Nov 1

Name

Proportion

VanEck Biotech ETF

9.42%

ProShares Ultra Nasdaq Biotechnology

8.56%

Invesco Nasdaq Biotechnology ETF

8.38%

iShares Biotechnology ETF

7.31%

Invesco Biotechnology & Genome ETF

4.96%

Natixis Loomis Sayles Focused Growth ETF

3.75%

First Trust NASDAQ Pharmaceuticals ETF

3.68%

Franklin Genomic Advancements ETF

2.99%

ETC 6 Meridian Quality Growth ETF

2.96%

Global X Genomics & Biotechnology ETF

2.83%

VanEck Biotech ETF

Proportion9.42%

ProShares Ultra Nasdaq Biotechnology

Proportion8.56%

Invesco Nasdaq Biotechnology ETF

Proportion8.38%

iShares Biotechnology ETF

Proportion7.31%

Invesco Biotechnology & Genome ETF

Proportion4.96%

Natixis Loomis Sayles Focused Growth ETF

Proportion3.75%

First Trust NASDAQ Pharmaceuticals ETF

Proportion3.68%

Franklin Genomic Advancements ETF

Proportion2.99%

ETC 6 Meridian Quality Growth ETF

Proportion2.96%

Global X Genomics & Biotechnology ETF

Proportion2.83%

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Split



Date

Type

Ratio

No Data

Date

Type

Ratio

No Data